{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:33:57Z","timestamp":1777919637818,"version":"3.51.4"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX10723204-007-001"],"award-info":[{"award-number":["2018ZX10723204-007-001"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572434"],"award-info":[{"award-number":["81572434"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Here, we report a case of postoperative recurrence of gallbladder carcinoma (GBC) in a patient who declined systemic chemotherapy. ATM S1905Ifs*25 and STK11 K262Sfs*25 mutations were detected by next-generation sequencing. Oral administration of olaparib was initiated. One month later, the patient experienced relief of clinical symptoms, a decrease in CA19-9 level, and a reduction in abnormal signal in the subcapsular region. The tumor response remained stable for approximately 13 months. This is the first case to demonstrate the clinical benefits of olaparib treatment in a patient with GBC harboring an ATM-inactivating mutation. This observation helps to better inform treatment options to enhance the care of patients with advanced GBC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:p>A patient with gallbladder carcinoma harboring an ATM-inactivating mutation responded to olaparib with a progression-free survival of 13 months. This is the first report that demonstrates the clinical benefits of olaparib treatment in a patient with gallbladder carcinoma with an ATM-inactivating mutation. It also highlights the importance of next-generation sequencing, which can provide valuable information for planning effective targeted therapies for gallbladder carcinoma. Evidence-based decisions help determine the best choice of treatment for individualized patient care.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0498","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T14:17:51Z","timestamp":1581430671000},"page":"375-379","source":"Crossref","is-referenced-by-count":21,"title":["Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an <i>ATM<\/i>-Inactivating Mutation"],"prefix":"10.1093","volume":"25","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China"},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junping","family":"Shi","sequence":"additional","affiliation":[{"name":"OrigiMed, Shanghai, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rentao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[{"name":"OrigiMed, Shanghai, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"2021122510314077400_onco13238-bib-0001","doi-asserted-by":"crossref","first-page":"12211","DOI":"10.3748\/wjg.v21.i43.12211","article-title":"Gallbladder carcinoma: Prognostic factors and therapeutic options","volume":"21","author":"Goetze","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2021122510314077400_onco13238-bib-0002","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/967472","article-title":"Gallbladder cancer in the 21st century","volume":"2015","author":"Kanthan","year":"2015","journal-title":"J Oncol"},{"key":"2021122510314077400_onco13238-bib-0003","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1634\/theoncologist.2009-0302","article-title":"Current management of gallbladder carcinoma","volume":"15","author":"Zhu","year":"2010","journal-title":"The Oncologist"},{"key":"2021122510314077400_onco13238-bib-0004","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"2021122510314077400_onco13238-bib-0005","doi-asserted-by":"crossref","first-page":"467","DOI":"10.21037\/atm.2019.08.67","article-title":"Precision oncology for gallbladder cancer: Insights from genetic alterations and clinical practice","volume":"7","author":"Lin","year":"2019","journal-title":"Ann Transl Med"},{"key":"2021122510314077400_onco13238-bib-0006","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"2021122510314077400_onco13238-bib-0007","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3030","article-title":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","volume":"46","author":"Li","year":"2014","journal-title":"Nat Genet"},{"key":"2021122510314077400_onco13238-bib-0008","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.hbpd.2018.09.011","article-title":"Trastuzumab, not lapatinib, has therapeutic effects on chinese patients with HER2-positive cholangiocarcinoma","volume":"17","author":"Mou","year":"2018","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"2021122510314077400_onco13238-bib-0009","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0693-2","article-title":"Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients","volume":"12","author":"Tang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2021122510314077400_onco13238-bib-0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021122510314077400_onco13238-bib-0011","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021122510314077400_onco13238-bib-0012","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122510314077400_onco13238-bib-0013","doi-asserted-by":"crossref","first-page":"R267","DOI":"10.1530\/ERC-16-0116","article-title":"Evaluation of the methods to identify patients who may benefit from parp inhibitor use","volume":"23","author":"Lim","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2021122510314077400_onco13238-bib-0014","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/annonc\/mdw048","article-title":"PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: Beyond germline BRCA mutations","volume":"27","author":"Helleday","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122510314077400_onco13238-bib-0015","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2014.60.0320","article-title":"Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer","volume":"33","author":"Bang","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122510314077400_onco13238-bib-0016","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122510314077400_onco13238-bib-0017","doi-asserted-by":"crossref","DOI":"10.21037\/hbsn.2019.04.11","article-title":"Somatic genetic aberrations in gallbladder cancer: Comparison between chinese and us patients","volume":"8","author":"Yang","year":"2019","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2021122510314077400_onco13238-bib-0018","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1073\/pnas.0308061100","article-title":"The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress","volume":"101","author":"Shaw","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122510314077400_onco13238-bib-0019","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1038\/sj.onc.1210594","article-title":"A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome","volume":"26","author":"Sanchez-Cespedes","year":"2007","journal-title":"Oncogene"},{"key":"2021122510314077400_onco13238-bib-0020","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1038\/sj.onc.1207665","article-title":"Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations","volume":"23","author":"Fernandez","year":"2004","journal-title":"Oncogene"},{"key":"2021122510314077400_onco13238-bib-0021","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.MP.0000075645.97329.86","article-title":"Loss of Stk11\/Lkb1 expression in pancreatic and biliary neoplasms","volume":"16","author":"Sahin","year":"2003","journal-title":"Mod Pathol"},{"key":"2021122510314077400_onco13238-bib-0022","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","article-title":"AMPK phosphorylation of raptor mediates a metabolic checkpoint","volume":"30","author":"Gwinn","year":"2008","journal-title":"Molecular Cell"},{"key":"2021122510314077400_onco13238-bib-0023","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2217\/cns-2016-0011","article-title":"Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy","volume":"5","author":"Donovan","year":"2016","journal-title":"CNS Oncol"},{"key":"2021122510314077400_onco13238-bib-0024","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1200\/JCO.2010.32.7825","article-title":"mTOR inhibitor treatment of pancreatic cancer in a patient with Peutz-Jeghers syndrome","volume":"29","author":"Kl\u00fcmpen","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2019-0498","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0498","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0498","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/5\/375\/41919961\/oncolo_25_5_375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/5\/375\/41919961\/oncolo_25_5_375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:32:08Z","timestamp":1640428328000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/5\/375\/6444362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,2,11]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0498","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5,1]]},"published":{"date-parts":[[2020,2,11]]}}}